Immunitas Therapeutics Email Format

Biotechnology ResearchMassachusetts, United States11-50 Employees

Immunitas Therapeutics is a biotechnology research company focused on discovering and developing novel therapeutics for cancer and autoimmune diseases. Its lead program, IMT-009, targets CD161 and is in clinical trials for patients with refractory tumors across indications such as MSS colorectal cancer, head and neck cancer, and non-small cell lung cancer. Its second program aims to treat autoimmune disease and builds on its work with the CD161-CLEC2D pathway. It is based in Waltham, Massachusetts, and operates as a small to mid-sized organization.

In addition to its internal programs, the company has engaged in partnerships, including a global licensing agreement announced in 2026 with Boehringer Ingelheim aimed at a preclinical antibody program for chronic inflammatory and autoimmune diseases. Immunitas has shared data on IMT-009, including phase 1/2a results indicating anti-tumor activity, at scientific meetings such as AACR 2026.

Sign up for free to view info

Company overview Employee directory